Acquisition-driven growth The IMA Group has a active M&A track record with multiple acquisitions across 2022-2025 (AmiciCR, Pontum Health, Medical Research Network, Chicago Research Center, etc.), signaling a strategic expansion of its clinical research network and evaluation services. This creates cross-sell opportunities across newly acquired sites and an expanding national footprint for government, payer, and corporate clients.

Expanded clinical network With thousands of licensed providers and over 150 offices nationwide, IMA presents a large, scalable network for faster trial recruitment, centralized evaluation services, and regional coverage for government and insurer contracts, which can appeal to sponsors seeking broad site access and diverse populations.

Therapeutic focus opportunities IMA operates across Phase II–IV trials in multiple therapeutic areas with emphasis on psychiatry, neurology, and CNS disorders through recent acquisitions, suggesting up-selling potential to sponsors in CNS, behavioral health, and related specialties requiring both clinical research capabilities and disability evaluations.

Regulatory and payer leverage IMA’s dual divisions in evaluation services for government and payer relationships create a unique value proposition for sponsors needing compliant, payer-aligned health assessments, disability evaluations, and streamlined administrative processes to support clinical trials and post-approval studies.

Leadership and scale Strategic hires in sales leadership and a growth-focused leadership team (e.g., SVP of Sales appointments) combined with rapid expansion signals a tuned go-to-market approach, offering potential for targeted outreach around enterprise contracts, sponsored trials, and national coverage initiatives.